Browse by Audience
Skip to content
Papers of the Week
New migraine prophylactic drugs: Current evidence and practical suggestions for non-responders to prior therapy.
Authors
Lee MJ, Al-Karagholi MA, Reuter UAbstract
Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (anti-CGRP(-R) mAbs) and small-molecule CGRP receptor antagonists (gepants) are new mechanism-based prophylactic drugs developed to address the unmet needs of pre-existing migraine prophylactic medications. However, several uncertainties remain in their real-world applications.